Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04668001 · ClinicalTrials.gov registry record · NA

Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome

A NA study of Down Syndrome, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
19
Enrollment target
1
Study location

NCT04668001: Active NA study of Down Syndrome, sponsored by Massachusetts General Hospital.

NCT04668001 is a NA study of Down Syndrome that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 19 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04668001, a NA study of Down Syndrome, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to better understand the effects of transcranial photobiomodulation (tPBM) on neural oscillations of individuals diagnosed with Down syndrome.

Conditions Studied

Interventions

  • DEVICE Near-Infrared Transcranial Photobiomodulation
  • DEVICE Sham Transcranial Photobiomodulation

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital at the Charlestown Navy Yard - Charlestown

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2021-10-19
Est. Completion 2024-09-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT04668001 still lists

NCT04668001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Near-Infrared Transcranial Photobiomodulation is the first listed.

NCT04668001 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04668001 about?

NCT04668001 is a clinical study titled "Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome". The aim of this study is to better understand the effects of transcranial photobiomodulation (tPBM) on neural oscillations of individuals diagnosed with Down syndrome.

What is the current status of trial NCT04668001?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 19 participants. The study started on 2021-10-19. Estimated completion is 2024-09-01.

What conditions does trial NCT04668001 study?

This clinical trial studies the following conditions: Down Syndrome.

What interventions are being tested in trial NCT04668001?

The interventions under investigation include: Near-Infrared Transcranial Photobiomodulation (DEVICE), Sham Transcranial Photobiomodulation (DEVICE).

Who is sponsoring clinical trial NCT04668001?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04668001 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04668001's enrollment target sits among peer trials

19 47th of 54 higher than 7 of 54 other Down Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Down Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04668001, the US trial registry maintained by the National Library of Medicine. NCT04668001 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.